SynthesisSexually transmitted diseases2017
Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis.
Synthesis in Sexually transmitted diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01832480 (Trichomonas Vaginalis Repeat Infections Among HIV Negative Women), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Global prevalence of Trichomonas vaginalis among female sex workers: a systematic review and meta-analysis.Parasitology research · 2021Pooled it
- Pooled it
- Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.Sexually transmitted diseases · 2019Trial
- Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.The Lancet. Infectious diseases · 2018Trial
- Multidose Metronidazole Treatment for Trichomonas vaginalis More Effective Than Single-Dose Treatment in Clinical Practice: A Retrospective Cohort Study.Sexually transmitted diseases · 2026Article
- Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development.Pharmaceutical research · 2026Review
- RefiningBMJ open · 2026Article
- The Role of the Vaginal Microbiome in Gynecological Diseases: Mechanistic Insights and Emerging Interventions.Biology · 2026Review
- Viral load dependent cellular heterogeneity in Trichomonas vaginalis at the single cell level.iScience · 2026Article
- Sexually Transmitted Infections in People with Human Immunodeficiency Virus.Infectious disease clinics of North America · 2024Review
- Trichomoniasis.Infectious disease clinics of North America · 2023Review
- Secnidazole: a treatment for trichomoniasis in adolescents and adults.Expert review of anti-infective therapy · 2022Article
- Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis.Diagnostics (Basel, Switzerland) · 2021Review
- Metronidazole-resistant trichomoniasis: Two Canadian cases.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2021Article
- Role of galectin-glycan circuits in reproduction: from healthy pregnancy to preterm birth (PTB).Seminars in immunopathology · 2020Review
- Article
- Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity.Current opinion in infectious diseases · 2020Review
- Pharmacokinetic and Pharmacodynamic Effects of Metronidazole May Account for the Superior Efficacy of Multidose Therapy Among Women With Trichomoniasis.Sexually transmitted diseases · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTrichomonas vaginalis is the most common curable sexually transmitted infection worldwide. Although the Centers for Disease Control and Prevention and the World Health Organization recommend a single 2-g dose of metronidazole for the first line of treatment for T. vaginalis among human immunodeficiency virus (HIV) negative women, high rates of repeat infections are found. The purpose of this meta-analysis was to compare treatment failure between single versus multidose metronidazole for the treatment of T. vaginalis.
methodsA systematic literature search was performed using search terms including metronidazole AND trichomoniasis AND women. Embase, MEDLINE, and Clinicaltrials.gov were used to search for relevant studies as well as hand searching relevant articles. These databases were last searched on January 25, 2016. To be included in this meta-analysis, the study had to be a clinical trial, evaluate T. vaginalis, use oral metronidazole, and compare single dose metronidazole to multidose metronidazole.
resultsThere were 487 articles that were assessed for relevance and quality. Of these articles, 6 met the eligibility criteria and were included in the final results. The pooled risk ratio indicated higher treatment failure for single dose compared to multidose 1.87 (95% confidence interval, 1.23-2.82; P < 0.01). When the one study that included HIV+ women was excluded from analysis, the findings were similar with a pooled risk ratio of 1.80 (95% confidence interval, 1.07-3.02; P < 0.03).
conclusionsCenters for Disease Control and Prevention recently changed treatment recommendations for HIV+ women to multidose rather than single-dose. These data suggest that those recommendations should be considered for all women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.